EUVIMEDScopri EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC-ND 4.0

A Retrospective Analysis of Human Angiotensin II Receptor Blockers (ARB) Pharmacokinetics, Dosages and C max Values for the Experimental Modelling of Pleiotropic and Supratherapeutic Activities

Alexandria Evans, Pascal Bernatchez

Basic & Clinical Pharmacology & Toxicology · 2026-04 · 138 (4)

DOI: 10.1111/bcpt.70203 ↗

At a glance

Übersichtsarbeit in Basic & Clinical Pharmacology & Toxicology, published online on 2026-03-12. Written by Alexandria Evans and 1 co-authors. Institution: Department of Anesthesiology, Pharmacology & Therapeutics, and Centre for Heart + Lung Innovation, St. Paul's Hospital, The University of British Col…. Major MEDLINE topics: Angiotensin II Type 1 Receptor Blockers, Models, Biological, Antihypertensive Agents. 119 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: CIHR, GADA Canada, Canadian Institutes for Health Research and GADA Canada.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Angiotensin II (AngII) receptor blockers (ARBs) are medications that lower systolic blood pressure (BP) by antagonizing the AngII type 1 receptor (AT1). However, ARBs have documented or suspected therapeutic properties in diseases not caused by high BP including diabetes, muscular dystrophy, chronic obstructive pulmonary diseases (COPD) and Alzheimer's disease. ARBs have multiple pleiotropic properties; ‘ on‐target ’ AT1‐dependent pleiotropy can arise from blocking AngII‐AT1 binding in non‐BP‐regulating cells or via inverse or biased ARB‐AT1 agonism. In addition, activation of cells lacking AT1 by ARBs suggests the presence of AT1‐independent ‘ off‐target ’ pleiotropy, whereas supratherapeutic properties in the absence of further BP lowering have also been reported. Herein, to determine how ARB pleiotropy and supratherapeutic properties can be modelled in vitro or ex vivo, we perform a retrospective analysis of the literature that characterizes their maximal human plasma concentration, C max , which is higher and more likely to trigger pleiotropy than their low nanomolar, AT1‐blocking concentrations. Our findings suggest that C max is variable and heterogeneous between ARBs, with upper range values as high as 13.6 micromolar in the case of valsartan and lower range values as low as 0.4 micromolar for candesartan. We propose that modelling of ARB pleiotropy be conducted at these concentrations, whereas higher concentrations will mimic supratherapeutic applications.

Subjects

MeSH terms (MEDLINE)

Angiotensin II Type 1 Receptor BlockersModels, BiologicalAntihypertensive AgentsHumansRetrospective StudiesBlood PressureTetrazolesReceptor, Angiotensin, Type 1Biphenyl CompoundsAnimalsDose-Response Relationship, DrugBenzimidazolesHypertensionValsartan

Substances

Angiotensin II Type 1 Receptor BlockersTetrazolesReceptor, Angiotensin, Type 1Biphenyl CompoundsBenzimidazolesAntihypertensive AgentsValsartancandesartan

Authors and institutions

  • Department of Anesthesiology, Pharmacology & Therapeutics, and Centre for Heart + Lung Innovation, St. Paul's Hospital, The University of British Columbia (UBC), Vancouver, Canada.

Funding

  • CIHR
  • GADA Canada
  • Canadian Institutes for Health Research and GADA Canada
  • Canadian Institutes of Health Research

Cite

APA

Evans, A., & Bernatchez, P. (2026). A Retrospective Analysis of Human Angiotensin II Receptor Blockers (ARB) Pharmacokinetics, Dosages and C max Values for the Experimental Modelling of Pleiotropic and Supratherapeutic Activities. Basic & Clinical Pharmacology & Toxicology, 138(4). https://doi.org/10.1111/bcpt.70203

Vancouver

Evans A, Bernatchez P. A Retrospective Analysis of Human Angiotensin II Receptor Blockers (ARB) Pharmacokinetics, Dosages and C max Values for the Experimental Modelling of Pleiotropic and Supratherapeutic Activities. Basic & Clinical Pharmacology & Toxicology. 2026;138(4). doi:10.1111/bcpt.70203

BibTeX
@article{Evans2026,
  author = {Evans, Alexandria and Bernatchez, Pascal},
  title = {A Retrospective Analysis of Human Angiotensin II Receptor Blockers (ARB) Pharmacokinetics, Dosages and C max Values for the Experimental Modelling of Pleiotropic and Supratherapeutic Activities},
  journal = {Basic & Clinical Pharmacology & Toxicology},
  year = {2026},
  volume = {138},
  number = {4},
  doi = {10.1111/bcpt.70203}
}
Start for free →